In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Minimally-Invasive Heart Valves, Edwards Cuts a Wide Swath

Executive Summary

Heart valves used in surgical procedures constitute more than 40% of the revenues of Edwards Lifesciences. So the company's recent acquisition of endovascular heart valve company Percutaneous Valve Technologies Inc. (PVT), along with its earlier acquisition of a percutaneous heart valve from Jomed NV, could be regarded as part of its plan to launch a pre-emptive strike. Edwards now has the broadest and most advanced portfolio of endovascular heart valve repair products in the industry. It thus hedges itself against the possible future erosion of its surgical valve franchise by the new interventional cardiology-oriented approaches and beats out Medtronic and Boston Scientific, each of which previously held 10% stakes in PVT before the acquisition.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts